Floatz logo

Capecitabine

Periampullary Adenocarcinoma

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Periampullary Adenocarcinoma cohort.

Asset / SponsorPhaseRating
HUMAN FIBRINOGEN
Asan Medical Center
Phase 4BB
N-BUTYL CYANOACRYLATE
Minia University
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2CCC
Cediranib
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →